NYSE · PAHC
Healthcare · Drug Manufacturers - Specialty & Generic
$37.24
Up+$1.37 (+3.82%)
Updated Oct 4, 2026, 6:29 AM
SID Score
4.7/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · PAHC
1M range · 19 trading sessions · Daily adjusted prices
Prices through Oct 2, 2026
PAHC closed at $37.24 after 19 trading sessions, down 0.19% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 2, 2026 | $36.19 | $37.615 | $36.19 | $37.24 | 222.74K |
| Oct 1, 2026 | $35.58 | $36.225 | $35.18 | $35.87 | 275.07K |
| Sep 30, 2026 | $35.68 | $36.02 | $35.06 | $35.74 | 205.54K |
| Sep 29, 2026 | $35.46 | $35.72 | $34.70 | $35.45 | 170.54K |
| Sep 28, 2026 | $34.25 | $36.13 | $33.84 | $35.70 | 485.9K |
| Sep 25, 2026 | $33.93 | $34.66 | $33.52 | $34.45 | 206.58K |
| Sep 24, 2026 | $34.10 | $34.2456 | $33.05 | $33.93 | 130.58K |
| Sep 23, 2026 | $35.14 | $36.0399 | $34.04 | $34.10 | 141.67K |
| Sep 22, 2026 | $35.10 | $35.54 | $34.91 | $35.15 | 204.03K |
| Sep 21, 2026 | $34.71 | $35.385 | $34.46 | $34.68 | 141.34K |
| Sep 18, 2026 | $34.12 | $35.11 | $34.12 | $34.56 | 635.51K |
| Sep 17, 2026 | $35.64 | $35.64 | $34.40 | $34.445 | 212.04K |
| Sep 16, 2026 | $35.03 | $35.98 | $34.68 | $35.30 | 269.52K |
| Sep 15, 2026 | $36.00 | $36.00 | $34.94 | $35.03 | 322.82K |
| Sep 14, 2026 | $35.92 | $36.70 | $35.835 | $35.94 | 258.36K |
| Sep 11, 2026 | $36.99 | $37.66 | $35.51 | $35.62 | 212.3K |
| Sep 10, 2026 | $36.80 | $36.96 | $36.295 | $36.58 | 174.06K |
| Sep 9, 2026 | $37.11 | $37.4599 | $36.60 | $36.80 | 176.89K |
| Sep 8, 2026 | $37.92 | $37.92 | $36.86 | $37.31 | 182.19K |
The latest Smart Investors Daily articles mentioning PAHC.
Company
Market Activity
Research & News
PAHC research
Company profile and research snapshot.
Phibro Animal Health Corp operates as a diversified animal health and mineral nutrition company. It develops, manufactures, and markets products for a range of food animals comprising poultry, swine, beef and dairy cattle, and aquaculture. The product portfolio of the company includes animal health products such as antibacterials, anticoccidials, nutritional specialty products and vaccines, and mineral nutrition products. The company operates through three segments, Animal Health, Mineral Nutrition, and Performance Products, of which key revenue is derived from the Animal Health segment which relates to the development, manufacturing, and marketing of antibacterials, nutritional specialty products, and vaccines. The entity sells its products in the U.S. and other international countries.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 14, 2026 | Citigroup | Neutral | — |
| Apr 15, 2026 | Citigroup | Neutral | — |
| Nov 7, 2025 | JP Morgan | Overweight | — |
| Aug 29, 2025 | B of A Securities | Underperform | — |
| Jul 7, 2025 | JP Morgan | Overweight | — |
No generated briefing is available yet.
Yahoo · Sep 28, 2026
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Yahoo · Sep 25, 2026
Phibro (PAHC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Yahoo · Sep 24, 2026
Shareholders of Phibro Animal Health would probably like to forget the past six months even happened. The stock dropped 38.5% and now trades at $34.11. This may have investors wondering how to approach the situation.
Yahoo · Sep 23, 2026
Let’s dig into the relative performance of Phibro Animal Health (NASDAQ:PAHC) and its peers as we unravel the now-completed Q2 branded pharmaceuticals earnings season.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning PAHC.
